Market Place
Sourcing Support
All News #Library
Rare Diseases
Biohaven CEO Calls Recent FDA Decisions `A Systemic Problem`
13 Feb 2026 //
FIERCE BIOTECH
FDA Rejects Biohaven Approval Request, Triggering Cost Cutting
06 Nov 2025 //
BIOSPACE
Biohaven Announces Positive Data for BHV-1400 in IgA Nephropathy
28 May 2025 //
PR NEWSWIRE
FDA Extends PDUFA Date for Biohaven`s Troriluzole NDA
14 May 2025 //
PR NEWSWIRE
Biohaven`s Taldefgrobep Alfa Receives EU Orphan Drug Designation
31 Jul 2023 //
PR NEWSWIRE
A blow for Biohaven as FDA refuses failed rare disease drug
27 Jul 2023 //
FIERCE BIOTECH
After rare disease failure, Biohaven pushes the gas on oral migraine drug
27 Nov 2017 //
FIERCE BIOTECH
Biohaven pushes the gas on oral migraine drug
27 Nov 2017 //
FIERCE BIOTECH
US FDA grants orphan drug status to Biohaven`s BHV-5000 to treat Rett syndrome
06 Jul 2017 //
PHARMABIZ
Biohaven Completes Enrollment In Spinocerebellar Ataxia Clinical Trial With Trigriluzole
30 May 2017 //
CLINICAL LEADER
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.